NR1H4 and metabolic dysfunction-associated steatotic liver disease: During the past decade, several clinical trials have been conducted to test the safety and effectiveness of OCA, a FXR ligand with 100 times higher affinity than chenodeoxycholic acid, in the treatment of NAFLD (Table 2).